CA2268742A1 - Agonistes recepteurs hematopoietiques chimeriques multifonctionnels - Google Patents

Agonistes recepteurs hematopoietiques chimeriques multifonctionnels Download PDF

Info

Publication number
CA2268742A1
CA2268742A1 CA002268742A CA2268742A CA2268742A1 CA 2268742 A1 CA2268742 A1 CA 2268742A1 CA 002268742 A CA002268742 A CA 002268742A CA 2268742 A CA2268742 A CA 2268742A CA 2268742 A1 CA2268742 A1 CA 2268742A1
Authority
CA
Canada
Prior art keywords
xaa
leu
ser
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002268742A
Other languages
English (en)
Inventor
Charles A. Mcwherter
Yiqing Feng
John P. Mckearn
Neena L. Summers
Nicholas R. Staten
Philip R. Streeter
John C. Minnerly
Nancy I. Minster
Susan L. Woulfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2268742A1 publication Critical patent/CA2268742A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouvelles protéines agonistes réceptrices hématopoïétiques chimériques multifonctionnelles, des ADN qui codent les protéines agonistes réceptrices hématopoïétiques chimériques multifonctionnelles, des procédés de préparation de protéines agonistes réceptrices hématopoïétiques chimériques multifonctionnelles et des procédés d'utilisation des protéines agonistes réceptrices hématopoïétiques chimériques multifonctionnelles.
CA002268742A 1996-10-25 1997-10-23 Agonistes recepteurs hematopoietiques chimeriques multifonctionnels Abandoned CA2268742A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2962996P 1996-10-25 1996-10-25
US60/029,629 1996-10-25
PCT/US1997/020037 WO1998017810A2 (fr) 1996-10-25 1997-10-23 Agonistes recepteurs hematopoietiques chimeriques multifonctionnels

Publications (1)

Publication Number Publication Date
CA2268742A1 true CA2268742A1 (fr) 1998-04-30

Family

ID=21850035

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268742A Abandoned CA2268742A1 (fr) 1996-10-25 1997-10-23 Agonistes recepteurs hematopoietiques chimeriques multifonctionnels

Country Status (17)

Country Link
EP (1) EP0935663A2 (fr)
JP (1) JP2001504689A (fr)
KR (1) KR100497423B1 (fr)
AR (1) AR010041A1 (fr)
AU (1) AU725547B2 (fr)
BR (1) BR9713668A (fr)
CA (1) CA2268742A1 (fr)
CZ (1) CZ295843B6 (fr)
IL (1) IL129565A0 (fr)
NO (1) NO991948L (fr)
NZ (1) NZ335382A (fr)
PL (1) PL333023A1 (fr)
RO (1) RO120919B1 (fr)
RU (2) RU2245887C2 (fr)
TW (2) TW200413407A (fr)
WO (1) WO1998017810A2 (fr)
ZA (1) ZA979607B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0973900A1 (fr) * 1997-04-11 2000-01-26 G.D. Searle & Co. PROTEINES CHIMERIQUES CONTENANT LE LIGAND flt3
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
WO2002101047A1 (fr) * 2001-06-12 2002-12-19 Smithkline Beecham Corporation Procede d'identification de composes modulant les activites du gene 1 de reponse primaire a l'epo, eprg1
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
WO2005047461A2 (fr) 2003-08-18 2005-05-26 The Regents Of The University Of California Bibliotheques d'affichage de polypeptides et procede de fabrication et d'utilisation de celle-ci
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
WO2007098548A1 (fr) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited Molécule et chimères de cette molécule
US8293685B2 (en) * 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
WO2015069489A1 (fr) 2013-11-06 2015-05-14 Merck Patent Gmbh Biomarqueur prédictif pour thérapie à base de promédicament activé par l'hypoxie
CA3133830A1 (fr) * 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Proteines chimeriques basees sur le ligand de la tyrosine kinase-3 de type fms (flt3l)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503050A4 (en) * 1990-09-28 1994-07-06 Ortho Pharma Corp Hybrid growth factors
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
NZ335382A (en) 2001-03-30
AU725547B2 (en) 2000-10-12
NO991948L (no) 1999-06-23
ZA979607B (en) 1999-04-28
WO1998017810A2 (fr) 1998-04-30
IL129565A0 (en) 2000-02-29
RO120919B1 (ro) 2006-09-29
RU2245887C2 (ru) 2005-02-10
PL333023A1 (en) 1999-11-08
RU2005105360A (ru) 2006-08-10
KR20000052812A (ko) 2000-08-25
BR9713668A (pt) 2000-03-08
TW591035B (en) 2004-06-11
EP0935663A2 (fr) 1999-08-18
TW200413407A (en) 2004-08-01
KR100497423B1 (ko) 2005-07-07
CZ295843B6 (cs) 2005-11-16
AR010041A1 (es) 2000-05-17
CZ132399A3 (cs) 1999-12-15
AU5165298A (en) 1998-05-15
NO991948D0 (no) 1999-04-23
JP2001504689A (ja) 2001-04-10
WO1998017810A3 (fr) 1998-10-15

Similar Documents

Publication Publication Date Title
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
US6730303B1 (en) Fused G-CSF and IL-3 proteins and uses thereof
CA2268742A1 (fr) Agonistes recepteurs hematopoietiques chimeriques multifonctionnels
KR100456212B1 (ko) 다기능성조혈수용체아고니스트
CA2268027A1 (fr) Nouveaux agonistes du recepteur flt-3
WO1997012985A9 (fr) Agonistes multifonctionnels des recepteurs hematopoietiques
CA2234042A1 (fr) Nouveaux agonistes du recepteur du g-csf
US20070081979A1 (en) Multi-functional chimeric hematopoietic receptor agonists
AU751498B2 (en) flt3 ligand chimeric proteins
AU722759B2 (en) Novel C-MPL receptor agonists
AU703627B2 (en) Interleuken-3 (IL-3) receptor agonists
MXPA99003875A (en) NOVEL flt-3 RECEPTOR AGONISTS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20071023